ERBB2 and neoplasm: Of the 18 positive NGS results, 10 (56%) were concordant with primary tumor molecular alterations, while discordant samples consisted of gain of HER2 amplification in 4 (22%) cases, loss of estrogen receptor (ER) expression in 3 (17%) cases, and loss of EGFR mutation in 1 (6%) case.